Hennion & Walsh Asset Management Inc. Makes New $1.73 Million Investment in Telix Pharmaceuticals Limited $TLX

Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) during the second quarter, Holdings Channel reports. The fund bought 150,138 shares of the company’s stock, valued at approximately $1,731,000.

Several other large investors have also modified their holdings of TLX. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. Bank of America Corp DE raised its stake in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares in the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the fourth quarter worth approximately $89,000. XY Capital Ltd purchased a new stake in Telix Pharmaceuticals during the first quarter worth $120,000. Finally, IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals during the second quarter worth $213,000.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Citigroup reduced their target price on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Price Performance

Shares of TLX stock opened at $12.00 on Wednesday. The business’s fifty day simple moving average is $10.55 and its 200-day simple moving average is $9.43. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals Limited has a 12-month low of $6.28 and a 12-month high of $12.60.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.